The Bruton tyrosine kinase inhibitor ibrutinib abrogates triggering receptor on myeloid cells 1-mediated neutrophil activation.
作者信息
Stadler Nicole, Hasibeder Astrid, Lopez Pamela Aranda, Teschner Daniel, Desuki Alexander, Kriege Oliver, Weber Alexander N R, Schulz Christoph, Michel Christian, Heβ Georg, Radsak Markus P
机构信息
Department of Hematology, Medical Oncology & Pneumology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany.
Institute for Cell Biology, Department of Immunology, Eberhardt Karls-University of Tübingen, Germany.
出版信息
Haematologica. 2017 May;102(5):e191-e194. doi: 10.3324/haematol.2016.152017. Epub 2017 Jan 25.
Abstract
摘要
相似文献
1
The Bruton tyrosine kinase inhibitor ibrutinib abrogates triggering receptor on myeloid cells 1-mediated neutrophil activation.布鲁顿酪氨酸激酶抑制剂依鲁替尼可消除髓系细胞触发受体1介导的中性粒细胞活化。
Haematologica. 2017 May;102(5):e191-e194. doi: 10.3324/haematol.2016.152017. Epub 2017 Jan 25.
2
Dasatinib inhibits proinflammatory functions of mature human neutrophils.达沙替尼抑制成熟人中性粒细胞的促炎功能。
Blood. 2012 May 24;119(21):4981-91. doi: 10.1182/blood-2011-07-369041. Epub 2012 Mar 12.
3
Triggering receptor expressed on myeloid cells-1 in neutrophil inflammatory responses: differential regulation of activation and survival.髓样细胞表达的触发受体-1在中性粒细胞炎症反应中的作用：激活与存活的差异调节
J Immunol. 2004 Apr 15;172(8):4956-63. doi: 10.4049/jimmunol.172.8.4956.
4
IL-8 enhances antibody-dependent cellular cytotoxicity in human neutrophils.
Immunol Cell Biol. 1995 Jun;73(3):234-8. doi: 10.1038/icb.1995.38.
5
Extracellular signal-regulated kinase inhibition by statins inhibits neutrophil activation by ANCA.他汀类药物对细胞外信号调节激酶的抑制作用可抑制抗中性粒细胞胞浆抗体介导的中性粒细胞活化。
Kidney Int. 2003 Jan;63(1):96-106. doi: 10.1046/j.1523-1755.2003.00718.x.
6
Idelalisib impairs TREM-1 mediated neutrophil inflammatory responses.依鲁替尼可削弱 TREM-1 介导的中性粒细胞炎症反应。
Sci Rep. 2018 Apr 3;8(1):5558. doi: 10.1038/s41598-018-23808-2.
7
Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy.依鲁替尼干扰治疗性CD20抗体的细胞介导抗肿瘤活性：对联合治疗的启示。
Haematologica. 2015 Jan;100(1):77-86. doi: 10.3324/haematol.2014.107011. Epub 2014 Oct 24.
8
Bruton Kinase Inhibitors in Chronic Lymphocytic Leukemia.布鲁顿激酶抑制剂在慢性淋巴细胞白血病中的应用
Anticancer Agents Med Chem. 2017;17(8):1040-1045. doi: 10.2174/1871520616666160928153342.
9
Normal but not altered mucins activate neutrophils.正常而非改变的黏蛋白可激活中性粒细胞。
Cell Tissue Res. 2004 Dec;318(3):545-51. doi: 10.1007/s00441-004-0957-8. Epub 2004 Oct 13.
10
Ibrutinib: a paradigm shift in management of CLL.依鲁替尼：慢性淋巴细胞白血病治疗的范式转变。
Expert Rev Hematol. 2014 Dec;7(6):705-17. doi: 10.1586/17474086.2014.977862.
引用本文的文献
1
Ibrutinib pharmacokinetics in B-lymphoproliferative disorders discloses exposure-related incidence of hypertension.依鲁替尼在B淋巴细胞增殖性疾病中的药代动力学揭示了高血压的暴露相关发生率。
J Hypertens. 2025 Mar 1;43(3):521-528. doi: 10.1097/HJH.0000000000003937. Epub 2025 Jan 15.
2
Inhibition of Bruton's tyrosine kinase restricts neuroinflammation following intracerebral hemorrhage.抑制布鲁顿酪氨酸激酶可限制脑出血后的神经炎症。
Theranostics. 2025 Jan 1;15(2):494-508. doi: 10.7150/thno.101024. eCollection 2025.
3
BTK inhibitor-induced defects in human neutrophil effector activity against Aspergillus fumigatus are restored by TNF-α.BTK 抑制剂诱导的人类中性粒细胞对烟曲霉效应器活性缺陷可被 TNF-α 恢复。
JCI Insight. 2024 May 7;9(12):e176162. doi: 10.1172/jci.insight.176162.
4
A Review on Role of Inflammation in Coronavirus Disease.炎症在冠状病毒病中的作用综述
Endocr Metab Immune Disord Drug Targets. 2024;24(13):1488-1505. doi: 10.2174/0118715303265274231204075802.
5
New anticancer therapeutics impact fungal pathobiology, infection dynamics, and outcome.新型抗癌疗法会影响真菌病理生物学、感染动态及治疗结果。
PLoS Pathog. 2023 Dec 21;19(12):e1011845. doi: 10.1371/journal.ppat.1011845. eCollection 2023 Dec.
6
Inflammatory pathways in COVID-19: Mechanism and therapeutic interventions.新冠病毒感染中的炎症通路：机制与治疗干预措施
MedComm (2020). 2022 Aug 1;3(3):e154. doi: 10.1002/mco2.154. eCollection 2022 Sep.
7
Invasive Fungal Infections and Targeted Therapies in Hematological Malignancies.血液系统恶性肿瘤中的侵袭性真菌感染与靶向治疗
J Fungi (Basel). 2021 Dec 10;7(12):1058. doi: 10.3390/jof7121058.
8
Clinical Trials of the BTK Inhibitors Ibrutinib and Acalabrutinib in Human Diseases Beyond B Cell Malignancies.布鲁顿酪氨酸激酶（BTK）抑制剂依鲁替尼和阿卡替尼在B细胞恶性肿瘤以外的人类疾病中的临床试验。
Front Oncol. 2021 Oct 28;11:737943. doi: 10.3389/fonc.2021.737943. eCollection 2021.
9
Multifaceted Immunomodulatory Effects of the BTK Inhibitors Ibrutinib and Acalabrutinib on Different Immune Cell Subsets - Beyond B Lymphocytes.布鲁顿酪氨酸激酶（BTK）抑制剂依鲁替尼和阿卡拉布替尼对不同免疫细胞亚群的多方面免疫调节作用——超越B淋巴细胞。
Front Cell Dev Biol. 2021 Aug 13;9:727531. doi: 10.3389/fcell.2021.727531. eCollection 2021.
10
Bruton tyrosine kinase inhibitors as potential therapeutic agents for COVID-19: A review.布鲁顿酪氨酸激酶抑制剂作为COVID-19的潜在治疗药物：综述
Metabol Open. 2021 Sep;11:100116. doi: 10.1016/j.metop.2021.100116. Epub 2021 Jul 29.
本文引用的文献
1
Neutrophil migration in infection and wound repair: going forward in reverse.中性粒细胞在感染和伤口修复中的迁移：逆向前行。
Nat Rev Immunol. 2016 May 27;16(6):378-91. doi: 10.1038/nri.2016.49.
2
Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib.接受依鲁替尼治疗的慢性淋巴细胞白血病患者体液免疫部分重建且感染减少。
Blood. 2015 Nov 5;126(19):2213-9. doi: 10.1182/blood-2015-04-639203. Epub 2015 Sep 3.
3
FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia.FDA 批准：依鲁替尼用于既往治疗过的套细胞淋巴瘤和既往治疗过的慢性淋巴细胞白血病患者。
Clin Cancer Res. 2015 Aug 15;21(16):3586-90. doi: 10.1158/1078-0432.CCR-14-2225.
4
Effect of kinase inhibitors on the therapeutic properties of monoclonal antibodies.激酶抑制剂对单克隆抗体治疗特性的影响。
MAbs. 2015;7(1):192-8. doi: 10.4161/19420862.2015.989020.
5
Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy.依鲁替尼干扰治疗性CD20抗体的细胞介导抗肿瘤活性：对联合治疗的启示。
Haematologica. 2015 Jan;100(1):77-86. doi: 10.3324/haematol.2014.107011. Epub 2014 Oct 24.
6
The promising impact of ibrutinib, a Bruton's tyrosine kinase inhibitor, for the management of lymphoid malignancies.布鲁顿酪氨酸激酶抑制剂依鲁替尼在治疗淋巴系统恶性肿瘤方面具有显著疗效。
Pharmacotherapy. 2014 Mar;34(3):303-14. doi: 10.1002/phar.1366. Epub 2013 Dec 12.
7
Distinct signaling cascades of TREM-1, TLR and NLR in neutrophils and monocytic cells.中性粒细胞和单核细胞中TREM-1、TLR和NLR的不同信号级联反应。
J Innate Immun. 2014;6(3):339-52. doi: 10.1159/000355892. Epub 2013 Nov 21.
8
Critical limb ischaemia is characterised by an increased production of whole blood reactive oxygen species and expression of TREM-1 on neutrophils.严重肢体缺血的特征是全血活性氧物质产生增加和中性粒细胞上 TREM-1 的表达。
Atherosclerosis. 2013 Aug;229(2):396-403. doi: 10.1016/j.atherosclerosis.2013.05.029. Epub 2013 Jun 18.
9
Bruton's Tyrosine Kinase (BTK) and Vav1 contribute to Dectin1-dependent phagocytosis of Candida albicans in macrophages.布鲁顿酪氨酸激酶（BTK）和 Vav1 有助于巨噬细胞中 Dectin1 依赖性对白念珠菌的吞噬作用。
PLoS Pathog. 2013;9(6):e1003446. doi: 10.1371/journal.ppat.1003446. Epub 2013 Jun 27.
10
TREM-1 as a potential therapeutic target in psoriasis.TREM-1 作为银屑病的潜在治疗靶点。
J Invest Dermatol. 2013 Jul;133(7):1742-51. doi: 10.1038/jid.2013.68. Epub 2013 Feb 13.
Zotero 插件